Ashleigh Murphy-Beiner

Assistant Psychologist at Imperial College London Centre for Psychedelic Research

Data updated

Papers

10 publications

Trials

0 clinical trials

Links

Research Footprint

Ashleigh Murphy-Beiner appears in 10 tracked papers (2020–2024), most studied alongside Psilocybin, LSD and Ayahuasca, across Anxiety Disorders, Depressive Disorders and Major Depressive Disorder (MDD).

Most-cited paper: Trial of Psilocybin versus Escitalopram for Depression (1334 citations).

Frequent co-authors: Robin Murphy, David Nutt and Robin Carhart-Harris.

Background & Research

A. Murphy-Beiner is a clinical researcher active in contemporary psychedelic science whose published and in-preparation work centres on the psychological sequelae of psychedelic use and on strategies for coping and integration. Their research portfolio, drawn from mixed-methods, qualitative and survey-based studies, includes investigation of ayahuasca’s ‘afterglow’ and its associations with mindfulness and cognitive flexibility; a mixed-methods study and qualitative analyses documenting extended difficulties following psychedelic use; and interview work exploring ontological shock and existential distress after powerful psychedelic experiences.

Murphy-Beiner has also contributed to research comparing therapeutic outcomes of psilocybin-assisted therapy against conventional antidepressant treatment (psilocybin therapy v. escitalopram), with interest in personality change and broader mental-health outcomes. Across these projects they emphasise rigorous qualitative methodology, participant-centred descriptions of challenging experiences, and practical supports and coping strategies for people experiencing protracted difficulties after psychedelic sessions. (Note: the full given name was not available in the supplied sources.)

Affiliations

Institutions, companies, and organisations Ashleigh Murphy-Beiner is associated with.